• About
    • Our Mission
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs & Pipelines
    • Full-Spectrum Approach
    • Our Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
    • Latest NTLA-2002 Data
  • Disease Focus
    • Overview
    • Transthyretin Amyloidosis
    • Hereditary Angioedema
    • Acute Myeloid Leukemia
    • Alpha-1 Antitrypsin Deficiency
    • Hodgkin Lymphoma
  • Patients & Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare Professionals
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
Intellia Therapeutics
  • Full-Spectrum Blog
  • Contact
  • About
    • Our Mission
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs
    & Pipelines
    • Full-Spectrum Approach
    • Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
  • Disease
    Focus
    • Transthyretin Amyloidosis
    • Hereditary Angioedema
    • Acute Myeloid Leukemia
    • Alpha-1 Antitrypsin Deficiency
    • Hodgkin Lymphoma
  • Patients &
    Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare
    Professionals
  • Investors &
    Media
    • Overview
    • Press Releases
    • Scientific Publications &
      Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Disease Focus

Disease Focus

  • Disease Focus
  • Transthyretin Amyloidosis
  • Hereditary Angioedema
  • Acute Myeloid Leukemia
  • Alpha-1 Antitrypsin Deficiency
  • Hodgkin Lymphoma

At Intellia, we focus on identifying opportunities that can positively transform the lives of people living with severe and life-threatening conditions. Learn more about the diseases we’re investigating.

Transthyretin Amyloidosis

Transthyretin Amyloidosis

Transthyretin amyloidosis is a rare, rapidly progressive disease caused by a build-up of misfolded transthyretin proteins produced by the liver.

Learn More
Hereditary Angioedema

Hereditary Angioedema

Hereditary angioedema is a rare, hereditary condition associated with frequent episodes or attacks of painful swelling in various parts of the body.

Learn More
Acute Myeloid Leukemia

Acute Myeloid Leukemia

Acute myeloid leukemia is a cancer of the blood and bone marrow. Without immediate treatment, it can spread quickly to other parts of the body.

Learn More
Alpha-1 Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) deficiency is a genetic disease in which the body does not make enough AAT, a protein that protects the lungs and liver.

Learn More
Hodgkin Lymphoma

Hodgkin Lymphoma

Hodgkin lymphoma (HL) is a cancer of the lymphatic system, which is part of the immune system. HL starts when there is a change to the DNA of a white blood cell, known as a lymphocyte.

Learn More
  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2023

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.

You are leaving the
Intellia Therapeutics, Inc. website.

You may return to the Intellia Therapeutics, Inc. website by closing the window to the third-party website you have opened. Do you wish to continue?

When you are ready to return to the Intellia Therapeutics, Inc. website, simply close the window to the third-party website you have opened.

Yes No